Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7113513 | 0.89 | EPHX1 (0.68) | EPHX1CASP2ALDH1A1 | |
| SCHEMBL31486286 | 0.88 | EPHX1 (0.50) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL8242454 | 0.87 | EPHX1 (0.72) | EPHX1CASP2ALDH1A1 | |
| SCHEMBL4023052 | 0.87 | EPHX1 (0.54) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL11015483 | 0.87 | EPHX1 (0.54) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL10545742 | 0.83 | EPHX1 (0.47) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL1442907 | 0.83 | HDAC3 (0.49) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL7705371 | 0.83 | HDAC1 (0.49) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL11639864 | 0.81 | EPHX1 (0.52) | EPHX1HDAC1HDAC3HDAC2HDAC11 | |
| SCHEMBL11019740 | 0.81 | EPHX1 (0.45) | EPHX1HDAC1HDAC3HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399431-B1 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1532134-B1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | EP | disclosed |
| EP-1495009-B1 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060020001-A1 | Use of cathepsin k inhibitors for the treatment of glaucoma | ALCON, INC. (CH) | 2006-01-26 | — | — | US | disclosed |
| US-6982263-B2 | Nitriles useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2005-07-14 | — | — | US | disclosed |
| EP-1532134-A1 | NOVEL THIOPHENE ACYL HYDRAZINO DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE | Aventis Pharma S.A. (FR) | 2005-05-25 | — | — | EP | disclosed |
| US-6878706-B1 | Cyanamides useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-04-12 | — | — | US | disclosed |
| EP-1495009-A2 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040247527-A1 | Multifunctional photodynamic agents for treating of disease | MPA TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| WO-2002100849-A2 | NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| EP-1246824-A1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Aventis Pharma S.A. (FR) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001047930-A1 | CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-07-05 | — | — | WO | disclosed |
| EP-0403889-B1 | Method for the preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AG (DE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0321833-B1 | Process for the preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| US-5153326-A | Preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AKTIENGESELLSCHAFT (DE) | 1992-10-06 | — | — | US | disclosed |
| US-5034538-A | Preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AKTIENGESELLSCHAFT (DE) | 1991-07-23 | — | — | US | disclosed |
| EP-0403889-A1 | Method for the preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AG (DE) | 1990-12-27 | — | — | EP | disclosed |
| US-4952701-A | Preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AKTIENGESELLSCHAFT (DE) | 1990-08-28 | — | — | US | disclosed |
| EP-0321833-A2 | Process for the preparation of 4-amino-1,2,4-triazol-5-ones | BAYER AG (DE) | 1989-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154048-A1 | Novel acyl hydrazino thiophene derivatives, process for preparing them, their use as medicinal products, pharmaceutical compositions and novel use | CTSZ, CTSE, CTSS | EPHX1 878/4885HDAC1 109/4885HDAC3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.